Company / Shareholders' Equity
ENDONOVO THERAPEUTICS, INC. Shareholders' Equity History
FY2011-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$32.2M
FY2022
5-year range
-$32.2M / -$11.4M
FY2018-FY2022
Trend
-104.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ENDONOVO THERAPEUTICS, INC. reports negative total equity of -$32M in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$32M in FY2022.
Declined from -$14M to -$32M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, shareholders' equity decreased 104.0% year-over-year.
- Peak shareholders' equity was recorded in FY2011.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$32.2M | -104.0% |
| FY2021 | -$15.8M | -9.7% |
| FY2020 | -$14.4M | +29.9% |
| FY2019 | -$20.5M | -80.0% |
| FY2018 | -$11.4M | -33.1% |
| FY2016 | -$8.6M | +7.7% |
| FY2015 | -$9.3M | -97.7% |
| FY2014 | -$4.7M | -6621.5% |
| FY2011 | $72.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026